Helpdesk

Sales contact

Home > Resources > How Kayentis reduces the CO2 emissions of your eCOA projects with its carbon neutral program

How Kayentis reduces the CO2 emissions of your eCOA projects with its carbon neutral program

Last updated: May 6, 2025

In 2020, we implemented a carbon neutral program for all our clinical trials.
Our goal? To reduce project CO2 emissions without impacting cost, quality or timelines.

Subscribe to our newsletter

Empowering patients through education – A structured approach to clinical...

Kayentis introduces its Patient Education Video Library to strengthen clinical...

Expanding investor confidence: The strategic value of Patient Reported Outcomes...

Leveraging the potential of Patient Reported Outcome (PRO) data to...

Gastrointestinal Tract Diseases Research: Moving Towards Patient-Centered Clinical Trials

The critical importance of Patient Reported Outcomes (PROs) for Emerging...

About the author

Marc Chaperon

Estelle brings 20+ years of experience in pre-clinical and clinical research from Top 5 Pharma and Biotech firms. Leading projects across Phases 1 to 4 in diverse therapeutic areas, she offers deep insights into clinical science, operations, and regulatory intricacies. Appointed as Chief Medical Officer at Kayentis in May 2019.

Meet us at the following events

SCDM 2025

Baltimore, Maryland, USA - 27-30 SEPT 2025

Annual Conference 2025 – SCDMLive

SCOPE Europe 2025

OCT 14-15 2025 • Barcelona, Spain

SCOPE Europe | Summit for Clinical Operations Executives | October 14-15, 2025 |Barcelona, Spain